Aptamer  has provided an update on its enzyme modulation projects and a development project with a top five pharmaceutical company. These together represent further important advancements in the Group’s licensing and development. With multiple non-exclusive licensing opportunities for its first enzyme-modulating Optimer® already in place, Aptamer has now received initial sales forecasts from its first partner for the first commercial enzyme inhibitor in one specific application area. This alone has the potential to cover c.15% of the Group’s annual overheads through passive income. With discussions also continuing to rapidly advance with a second partner plus a third having signed a Material Transfer Agreement (‘MTA’), a high level of interest in Optimer® binders to provide new solutions in this field is clearly being demonstrated. These present opportunity for relatively quick conversion into additional medium-to-longer term royalty streams, either of which could become substantially larger than the one already indicated. The Group’s second enzyme-modulating Optimer® project has now also reached its final development stage, while a top five pharmaceutical customer has placed repeat orders for Optimer® binders to support its expanded internal testing and evaluation of ELISA (enzyme-linked immunosorbent assay) technology. These different milestones further validate the performance of Aptamer’s Optimer® platform, underscoring its commercial potential for provision of innovative antibody-alternative solutions, along with broader applications/strategic licensing potential in diagnostics and therapeutics. Retaining IP ownership provides Aptamer with opportunities for future licensing revenues, therein aligning its strategy to build long-term value through repeat business and commercialisation pathways.